fb-pixel Skip to main content

Latest Headlines in Biotech


A health care worker prepares to administer a dose of the Pfizer-BioNTech COVID-19 vaccine.

Four things to know about the FDA panel’s booster shot vote

After a panel of advisers to the Food and Drug Administration voted to recommend Pfizer booster shots for people over 65 or at high risk, what happens next?

Jason Kelly, CEO of Ginkgo Bioworks.

‘New bio nerds on the block’: Ginkgo Bioworks goes public, now valued at $20 billion

The deal generated more than $1.6 billion in proceeds for Ginkgo, making it one of the largest public debuts for a life sciences company.

Pedestrians walk past Biogen headquarters in Cambridge.

Biogen loses $7 billion in value on slow Alzheimer’s drug rollout

Only about 50 sites have been infusing the medication since June, well below company’s prior target of 900 centers, according to RBC analyst Brian Abrahams.

Emulate's "organ-on-a-chip" contains tiny hollow channels lined with tens of thousands of living human cells and tissues and can be used to predict human response.

Biotech behind ‘organ-on-a-chip’ systems raises $82 million

Emulate, based in Boston, uses plastic chips to simulate human organs to test whether drugs are safe and effective.

Biogen's headquarters in Cambridge.

House committees demand FDA records on Alzheimer’s drug approval

“We are concerned by apparent anomalies in FDA’s processes surrounding its review of Aduhelm,” the committee chairs said in a 13-page letter asking for a raft of documentation and answers to questions.

State Senator Joe Boncore will become the new head of the Massachusetts Biotechnology Council.

MassBio taps another state lawmaker as its leader

State Senator Joseph Boncore is the third consecutive current or former legislator to run the trade group for the state’s booming biotechnology industry.

An image of Endless RNA, or eRNA, shows how the molecule invented at Flagship Pioneering can latch onto a ribosome to make proteins.

As RNA remains hot, Flagship’s Laronde raises $440m for a new class of medicines

Laronde is based on a proprietary molecule its scientists call “endless RNA,” which the company hopes will allow humans to produce their own proteins for weeks or months to treat diseases.

The Moderna COVID-19 vaccine.

Moderna seeks full FDA approval for its COVID-19 vaccine

If regulators grant the approval, it would follow the full clearance earlier this week of the vaccine made by Pfizer and BioNTech.